{"id":"niacin-laropiprant","safety":{"commonSideEffects":[{"rate":null,"effect":"Flushing"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Gastrointestinal upset"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Niacin (vitamin B3) works as a lipid-modifying agent by inhibiting hepatic diacylglycerol acyltransferase-2 (DGAT2) and affecting lipoprotein metabolism. Laropiprant blocks the DP1 prostaglandin receptor, which mediates the vasodilatory flushing response that commonly limits niacin tolerability. The combination allows higher niacin doses to be used with improved tolerability.","oneSentence":"Niacin reduces triglycerides and LDL cholesterol while raising HDL cholesterol; laropiprant is a prostaglandin D2 receptor antagonist that reduces niacin-induced flushing.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:34:59.672Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dyslipidemia (elevated triglycerides and/or low HDL cholesterol) in patients at risk for cardiovascular disease"}]},"trialDetails":[{"nctId":"NCT01274559","phase":"PHASE3","title":"Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-03-01","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":1173},{"nctId":"NCT01308203","phase":"PHASE4","title":"Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease","status":"TERMINATED","sponsor":"Daniel A. Siniawski","startDate":"2011-10","conditions":"Coronary Artery Disease, Dyslipidemias","enrollment":32},{"nctId":"NCT01054508","phase":"PHASE4","title":"Effect of Tredaptive on Serum Lipoproteins and Inflammatory Markers","status":"COMPLETED","sponsor":"Manchester University NHS Foundation Trust","startDate":"2010-06","conditions":"Hypercholesterolemia","enrollment":38},{"nctId":"NCT00769132","phase":"PHASE1","title":"A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-08-03","conditions":"Hypercholesterolemia","enrollment":26},{"nctId":"NCT01683656","phase":"PHASE4","title":"ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART","status":"TERMINATED","sponsor":"Calmy Alexandra","startDate":"2012-08","conditions":"HIV, Atherosclerosis","enrollment":4},{"nctId":"NCT01118598","phase":"PHASE4","title":"Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"Hull University Teaching Hospitals NHS Trust","startDate":"2010-06","conditions":"Polycystic Ovary Syndrome","enrollment":34},{"nctId":"NCT00479882","phase":"PHASE3","title":"MK-0524B Lipid Study (MK-0524B-063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06-15","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":2414},{"nctId":"NCT01335997","phase":"PHASE3","title":"Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-05-01","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":1139},{"nctId":"NCT00289900","phase":"PHASE3","title":"Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-01-24","conditions":"Mixed Hyperlipidemia","enrollment":2340},{"nctId":"NCT01294683","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-02-04","conditions":"Primary Hypercholesterolemia, Dyslipidemia","enrollment":977},{"nctId":"NCT00533312","phase":"PHASE2","title":"MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-04","conditions":"Hypercholesterolemia","enrollment":407},{"nctId":"NCT00269217","phase":"PHASE3","title":"Lipid Efficacy Study (0524B-022)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-01","conditions":"Primary Hypercholesterolemia, Mixed Hyperlipidemia","enrollment":1400},{"nctId":"NCT00111891","phase":"PHASE2","title":"An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-06","conditions":"Dyslipidemia","enrollment":575},{"nctId":"NCT00376584","phase":"PHASE3","title":"Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-07","conditions":"Hypercholesteremia, Hyperlipidemia","enrollment":825},{"nctId":"NCT00378833","phase":"PHASE3","title":"Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-07","conditions":"Hypercholesterolemia, Hyperlipidemia","enrollment":1300},{"nctId":"NCT01052311","phase":"PHASE4","title":"The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients","status":"TERMINATED","sponsor":"Sheba Medical Center","startDate":"2010-07","conditions":"Coronary Artery Disease, Dyslipidemia","enrollment":8},{"nctId":"NCT01583647","phase":"PHASE1","title":"A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-06","conditions":"Hypercholesterolemia, Familial, Heterozygous Familial Hypercholesterolemia","enrollment":10},{"nctId":"NCT01012219","phase":"PHASE1","title":"A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11","conditions":"Primary Hypercholesterolemia, Mixed Hyperlipidemia","enrollment":36},{"nctId":"NCT00485758","phase":"PHASE3","title":"Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Diabetes Mellitus Type 2","enrollment":796},{"nctId":"NCT00384293","phase":"PHASE3","title":"Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-09","conditions":"Hypercholesterolemia, Familial","enrollment":937},{"nctId":"NCT00618995","phase":"PHASE1","title":"A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-08","conditions":"Type 2 Diabetes Mellitus","enrollment":26},{"nctId":"NCT00536510","phase":"PHASE3","title":"Effect of MK0524A on Cholesterol Levels (0524A-048)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-04","conditions":"Hypercholesterolemia, Hyperlipidemia","enrollment":646},{"nctId":"NCT00536237","phase":"PHASE2","title":"MK0524A Phase IIb Study (0524A-011)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-08","conditions":"Flushing","enrollment":154},{"nctId":"NCT00269204","phase":"PHASE3","title":"Lipid Efficacy/Tolerability Study (0524A-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-12","conditions":"Primary Hypercholesterolaemia, Mixed Hyperlipidaemia","enrollment":1620},{"nctId":"NCT00943124","phase":"PHASE1","title":"MK0524B Bioequivalence Study (0524B-070)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Dyslipidemia","enrollment":220},{"nctId":"NCT00944645","phase":"PHASE1","title":"MK0524A Bioequivalence Study (0524A-059)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-10","conditions":"Dyslipidemia","enrollment":188},{"nctId":"NCT01414166","phase":"PHASE3","title":"Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-09","conditions":"Dyslipidemia","enrollment":244},{"nctId":"NCT01228019","phase":"","title":"Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-12","conditions":"Hypercholesterolemia, Mixed Dyslipidemia","enrollment":1166},{"nctId":"NCT00664287","phase":"PHASE3","title":"Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-09","conditions":"Dyslipidemia","enrollment":""},{"nctId":"NCT00479388","phase":"PHASE3","title":"Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":1216},{"nctId":"NCT00961636","phase":"PHASE3","title":"A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-10","conditions":"Dyslipidemia","enrollment":1152},{"nctId":"NCT02153879","phase":"PHASE4","title":"Characterization of High Density Lipoprotein (HDL) in Type 2 Diabetes (T2D) After Fenofibrate or Niacin Treatment","status":"COMPLETED","sponsor":"Institut Investigacio Sanitaria Pere Virgili","startDate":"2009-02","conditions":"Type 2 Diabetes Mellitus, Dyslipidemia","enrollment":30},{"nctId":"NCT01239992","phase":"PHASE4","title":"Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia","status":"TERMINATED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2011-06","conditions":"Hyperlipoproteinemia, Metabolic Syndrome","enrollment":12},{"nctId":"NCT00461630","phase":"PHASE3","title":"Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2007-01","conditions":"Cardiovascular Disease, Peripheral Arterial Disease, Diabetes Mellitus","enrollment":25673},{"nctId":"NCT01942291","phase":"PHASE4","title":"Short-term Effect of Extended-release Niacin on Endothelial Function.","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2012-03","conditions":"Hypoalphalipoproteinemia","enrollment":18},{"nctId":"NCT01391377","phase":"NA","title":"Effects of Niacin on Good Cholesterol in People With Peripheral Arterial Disease","status":"TERMINATED","sponsor":"Bayside Health","startDate":"2011-07","conditions":"Peripheral Arterial Disease","enrollment":7},{"nctId":"NCT01450410","phase":"PHASE4","title":"Nicotinic Acid Composition of HDL and Arterial Endothelium Function in Premature Coronary Heart Disease and High HDL","status":"TERMINATED","sponsor":"Xavier Pinto Sala","startDate":"2012-07","conditions":"Dyslipidemias","enrollment":12},{"nctId":"NCT01321034","phase":"PHASE4","title":"Effect of Niacin in the Lipoprotein (a) Concentration","status":"COMPLETED","sponsor":"Instituto Aragones de Ciencias de la Salud","startDate":"2011-10","conditions":"Hypercholesterolemia","enrollment":90},{"nctId":"NCT01126073","phase":"PHASE4","title":"Niacin/Laropiprant and Endothelial Function","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2010-09","conditions":"Coronary Heart Disease","enrollment":60},{"nctId":"NCT01010516","phase":"PHASE4","title":"Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia","status":"UNKNOWN","sponsor":"University of Ioannina","startDate":"2009-10","conditions":"Dyslipidemia","enrollment":120},{"nctId":"NCT01071525","phase":"PHASE3","title":"The Effect of Niacin Administration on Oxidative Stress in Patients With Hypercholesterolmia, as Measured by the Use of a Novel Biomarker","status":"UNKNOWN","sponsor":"Rambam Health Care Campus","startDate":"2010-04","conditions":"Hypercholesterolemia","enrollment":30}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"BLOOD GLUCOSE INCREASED"},{"count":2,"reaction":"DRUG-INDUCED LIVER INJURY"},{"count":1,"reaction":"ADVERSE EVENT"},{"count":1,"reaction":"BRONCHITIS"},{"count":1,"reaction":"CARDIAC FAILURE CONGESTIVE"},{"count":1,"reaction":"CHEST PAIN"},{"count":1,"reaction":"COUGH"},{"count":1,"reaction":"DEATH"},{"count":1,"reaction":"DEFAECATION URGENCY"},{"count":1,"reaction":"FLUSHING"}],"_approvalHistory":[],"publicationCount":60,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tredaptive","EU/1/08/459/001"],"phase":"marketed","status":"active","brandName":"Niacin/ Laropiprant","genericName":"Niacin/ Laropiprant","companyName":"Ludwig-Maximilians - University of Munich","companyId":"ludwig-maximilians-university-of-munich","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Niacin reduces triglycerides and LDL cholesterol while raising HDL cholesterol; laropiprant is a prostaglandin D2 receptor antagonist that reduces niacin-induced flushing. Used for Dyslipidemia (elevated triglycerides and/or low HDL cholesterol) in patients at risk for cardiovascular disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}